Lantern Pharma Inc. (LTRN)
NASDAQ: LTRN · Real-Time Price · USD
2.860
+0.080 (2.88%)
At close: Aug 7, 2026, 4:00 PM EDT
2.852
-0.008 (-0.27%)
After-hours: Aug 7, 2026, 7:34 PM EDT
Lantern Pharma Employees
Lantern Pharma had 16 employees as of December 31, 2025. The number of employees decreased by 8 or -33.33% compared to the previous year.
Employees
16
Change (1Y)
-8
Growth (1Y)
-33.33%
Revenue / Employee
n/a
Profits / Employee
-$994,489
Market Cap
36.49M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) | Full-Time | Part-Time |
|---|---|---|---|---|---|
| Dec 31, 2025 | 16 | -8 | -33.33% | 16 | 0 |
| Dec 31, 2024 | 24 | 3 | 14.29% | 24 | 0 |
| Dec 31, 2023 | 21 | -2 | -8.70% | 21 | 0 |
| Dec 31, 2022 | 23 | 7 | 43.75% | 22 | 1 |
| Dec 31, 2021 | 16 | 1 | 6.67% | 14 | 2 |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Aligos Therapeutics | 82 |
| BeyondSpring | 44 |
| Veru Inc. | 20 |
| Serina Therapeutics | 16 |
| CervoMed | 15 |
| Apollomics | 14 |
| Nutriband | 13 |
| Hyperion DeFi | 9 |
LTRN News
- 2 days ago - Lantern Pharma to Report Second Quarter 2026 Operating & Financial Results on August 14th, 2026 at 9:00 a.m. ET - Business Wire
- 6 days ago - Lantern Pharma establishes Open-Medicine AI as separate company - TheFly
- 6 days ago - Lantern Pharma (Nasdaq: LTRN) Establishes Open-Medicine AI as a Separate Company to Commercialize and Expand Its Multi-Agent AI Co-Scientist Platform for the Transformation of Medicine - Business Wire
- 12 days ago - Lantern Pharma to advance EMA-cleared Phase 1b/2 trial of LP-184 - TheFly
- 12 days ago - Lantern Pharma to Advance EMA-Cleared Phase 1b/2 Trial of LP-184 (Zirdafulven) in Biomarker-Selected Advanced Bladder Cancer - Business Wire
- 17 days ago - Lantern Pharma receives USPTO notice of allowance for patent of LP-184 - TheFly
- 17 days ago - Lantern Pharma Receives USPTO Notice of Allowance for Patent Covering Biomarker-Guided Treatment with LP-184 (Zirdafulven) in Multiple Solid Tumor Cancers - Business Wire
- 4 weeks ago - Lantern Pharma launches ZetaOmics computational-biology module - TheFly